In addition to Stifel Nicolaus, Viking Therapeutics also received a Buy from William Blair’s Andy Hsieh in a report issued today. However, yesterday, Citi maintained a Hold rating on Viking ...

In a population not selected for risk, the cumulative incidence of atopic dermatitis at 24 months was 36.1% for those in the daily emollients group versus 43% for those in the control group (relative ...

Reports that the Trevi Fountain will be the next Italian attraction to start charging visitors a fee have sparked controversy ...

Rome switched off the lights of its iconic Trevi Fountain for one hour in a symbolic and urgent appeal for a ceasefire in ...

Rome dimmed the lights of the iconic Trevi Fountain for one hour Friday night in a symbolic call for a ceasefire in the Gaza Strip, following a city council resolution last month that was titled, ...

In a report released yesterday, Faisal Khurshid from Leerink Partners reiterated a Buy rating on Zura Bio. The company’s shares closed yesterday at $1.96. Elevate Your Investing ...

Rome dimmed the lights of the iconic Trevi Fountain for one hour Friday night in a symbolic call for a ceasefire in the Gaza ...

Trevi Therapeutics, Inc. (TRVI) closed the last trading session at $6.41, gaining 3.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

NEW HAVEN, Conn., June 5, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral ...

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in ...